Search results for "Neoplastic"

showing 10 items of 2901 documents

cis-Dichloroplatinum(II) complexes tethered to dibenzo[c,h][1,6]naphthyridin-6-ones: Synthesis and cytotoxicity in human cancer cell lines in vitro

2013

A novel family of cisplatin-type complexes tethered to dibenzo[c,h][1,6]naphthyridin-6-one topoisomerase inhibitor via a polymethylene chain and their nonplatinated counterparts were prepared. Their potential cytotoxicity was assessed in three human colorectal cancer cell lines HCT 116, SW480 and HT-29 and compared to the reference molecules cisplatin and oxaliplatin. Platinated compounds were poorly active whilst nonplatinated dibenzo[c,h][1,6]naphthyridin-6-one moieties exhibited higher cytotoxic properties than cisplatin and oxaliplatin whatever the length of the polymethylene chain; molecules containing the tri- and hexamethylene chain length were the most cytotoxic.

Organoplatinum Compoundsmedicine.drug_classStereochemistryAntineoplastic AgentsStructure-Activity RelationshipCell Line TumorDrug DiscoverymedicineHumansCytotoxic T cellMoleculeNaphthyridinesCytotoxicityCell ProliferationPharmacologyCisplatinDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryGeneral MedicineHCT116 CellsIn vitroOxaliplatinCell cultureDrug Screening Assays AntitumorHT29 CellsTopoisomerase inhibitormedicine.drugEuropean Journal of Medicinal Chemistry
researchProduct

Membrane gangliosides and immuno-mediated cytolysis in drug sensitive and treatment-induced multidrug resistant human ovarian cancer cells

1991

The pattern of cytoplasmic membrane gangliosides and two cellular features which have been reported to be related to the expression of different membrane gangliosides, namely adhesion to solid substrates and susceptibility to the lytic activity of immune effector cells, have been investigated in drug sensitive A2780 human ovarian cancer cells and in two treatment-induced multidrug resistant sublines (A2780-DX1 and A2780-DX3). The total membrane gangliosides content of A2780 sensitive cells was comparable to that of the two multidrug resistant (MDR) sublines, but the acquisition of the MDR phenotype was characterized by an increased expression of the polysialylated gangliosides (particularly…

Ovarian NeoplasmsDrug ResistanceMembrane ProteinsAntineoplastic AgentsMembrane gangliosides immunotherapyNeoplasm ProteinsPhenotypeDoxorubicinGangliosidesMultidrug resistance.Cell AdhesionTumor Cells CulturedHumansFemaleLymphocytesKiller Cells Lymphokine-Activated
researchProduct

Metal complexes of oxadiazole ligands: An overview

2019

Oxadizoles are heterocyclic ring systems that find application in different scientific disciplines, from medicinal chemistry to optoelectronics. Coordination with metals (especially the transition ones) proved to enhance the intrinsic characteristics of these organic ligands and many metal complexes of oxadiazoles showed attractive characteristics for different research fields. In this review, we provide a general overview on different metal complexes and polymers containing oxadiazole moieties, reporting the principal synthetic approaches adopted for their preparation and showing the variety of applications they found in the last 40 years.

OxadizoleAnti-Inflammatory AgentsOxadiazoleAntineoplastic AgentsReviewmetal complexes010402 general chemistryRing (chemistry)01 natural sciencesCatalysisInorganic ChemistryMetallcsh:ChemistryAntineoplastic Agentchemistry.chemical_compoundOrganometallic CompoundsPhysical and Theoretical ChemistryMolecular Biologylcsh:QH301-705.5SpectroscopyScientific disciplinesGroup 2 organometallic chemistryOrganometallic CompoundOxadiazoles010405 organic chemistryChemistryMetalOrganic ChemistryGeneral MedicineCombinatorial chemistry0104 chemical sciencesComputer Science ApplicationsAnti-Inflammatory Agent124-oxadizolelcsh:Biology (General)lcsh:QD1-999MetalsSettore CHIM/03 - Chimica Generale E Inorganicavisual_artvisual_art.visual_art_mediumMetal complexe134-oxadizole
researchProduct

miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance

2015

AbstractThe ErbB tyrosine kinase receptor family has been shown to have an important role in tumorigenesis, and the expression of its receptor members is frequently deregulated in many types of solid tumors. Various drugs targeting these receptors have been approved for cancer treatment. Particularly, in breast cancer, anti-Her2/EGFR molecules represent the standard therapy for Her2-positive malignancies. However, in a number of cases, the tumor relapses or progresses thus suggesting that not all cancer cells have been targeted. One possibility is that a subset of cells capable of regenerating the tumor, such as cancer stem cells (CSCs), may not respond to these therapeutic agents. Accumula…

P63cancer stem cellsCancer ResearchReceptor ErbB-2oncogenesmedicine.medical_treatmentmedicine.disease_causeTargeted therapyERBB3Molecular Targeted TherapyDEATHErbB ReceptorsGene Expression Regulation NeoplasticNeoplastic Stem CellsFemaleOriginal Articlemedicine.drugCARCINOMAMIGRATIONCancer Stem Cells; Breast CancerImmunologyBreast NeoplasmsCancer Stem CellMIR-205miR-205-5pBiologyLapatinibcancer treatmentNOCellular and Molecular Neurosciencebreast cancerBreast cancerErbBCancer stem cellCell Line TumormedicineHumansSUPPRESSIONCell ProliferationMESENCHYMAL TRANSITIONtumorigenesis cancer treatment cancer stem cells miR-205-5p oncogenes breast cancerMICRORNA EXPRESSIONTumor Suppressor ProteinsLapatinibCell BiologyTrastuzumabmedicine.diseaseGENEMicroRNAstumorigenesisDrug Resistance NeoplasmCancer cellQuinazolinesCancer researchNeoplasm Recurrence LocalCarcinogenesisTranscription FactorsCell Death & Disease
researchProduct

Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatect…

2014

Purpose: miRNAs are noncoding RNAs that negatively regulate target mRNA gene expression. Aberrant miRNA expression is associated with prostate cancer pathogenesis. We identified miRNAs as potential biomarkers for prostate cancer diagnosis and prognosis. Materials and Methods: Total RNA was obtained from 10 normal prostate and 50 prostate cancer samples, and analyzed using the GeneChip (R) miRNA 2.0 Array. At a median followup of 92 months (range 2 to 189) an independent cohort of 273 paraffin embedded prostate cancer samples was used for validation by quantitative reverse transcriptase-polymerase chain reaction. Another 92 urine samples from patients undergoing prostate biopsy were evaluate…

PCA3OncologyMalemedicine.medical_specialtyPathologyProstate biopsydiagnosisUrologymedicine.medical_treatmentprostatic neoplasmsProstate cancerProstateInternal medicinemicroRNAmedicineBiomarkers TumorHumansAgedRetrospective StudiesProstatectomymedicine.diagnostic_testbusiness.industryProstatectomyProstatic Neoplasmsmedicine.diseasePrognosismicroRNAsGene Expression Regulation NeoplasticProstate-specific antigenMicroRNAsmedicine.anatomical_structureReal-time polymerase chain reactionEarly Diagnosisprognosisbusinessbiological markersThe Journal of urology
researchProduct

French Endocrine Society Guidance on endocrine side effects of immunotherapy.

2018

The management of cancer patients has changed due to the considerably more frequent use of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a risk of side effects, particularly endocrine toxicity. Since the indications for ICPI are constantly expanding due to their efficacy, it is important that endocrinologists and oncologists know how to look for this type of toxicity and how to treat it when it arises. In view of this, the French Endocrine Society initiated the formulation of a consensus document on ICPI-related endocrine toxicity. In this paper, we will introduce data on the general pathophysiology of endocrine toxicity, and we will then outline expert opinion focusing…

PD-L1Cancer Researchmedicine.medical_specialtyHypophysitisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentImmune checkpoint inhibitorsimmune checkpoint inhibitorEndocrine System DiseasesGuidelines and GuidanceEndocrinologyAntineoplastic Agents ImmunologicalPD-1medicineAdrenal insufficiencyEndocrine systemHumansIn patientthyrotoxicosisIntensive care medicinediabetesbusiness.industryCommon Terminology Criteria for Adverse EventsImmunotherapymedicine.diseaseFrequent usehypophysitisOncologyCTLA-4FranceImmunotherapyhypothyroidismbusinessadrenal insufficiencyEndocrine-related cancer
researchProduct

Between Scylla and Charibdis: eIF2α kinases as targets for cancer chemotherapy

2011

[EN] The eIF2 alpha kinases integrate translation initiation rates with nutrient availability, thus allowing cells to adapt to nutrient scarcity. Recent evidence has uncovered new functions of these kinases in tumour cell biology, ranging from regulation of cell cycle progression, maintenance of genome stability, control of apoptosis, and cell survival under nutrient stress and hypoxia. Accordingly, active eIF2 alpha kinases modulate the antineoplasic activity of several antitumour drugs, either by exacerbating their cytotoxic effect or by promoting chemoresistance. Understanding of eIF2 alpha kinases molecular roles may provide mechanistic insights into how tumour cells sense and adapt to …

PERKBioquímicaTranslationBiologiaCancer ResearchCancer chemotherapyEukaryotic Initiation Factor-2Antineoplastic AgentsBiologyBioinformaticsNeoplasmsBIOQUIMICA Y BIOLOGIA MOLECULARHumansCytotoxic T cellCell survivalGenome stabilityKinaseNutrient stressPKRGeneral MedicineProtein kinase ROncologyApoptosiseIF2 alpha phosphorylationCancer researchGCN2Clinical and Translational Oncology
researchProduct

The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma

2009

Wild-type KRAS status is required but not sufficient to confer sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) in colorectal cancer patients. As a consequence, one of the major challenges is to identify, in non-mutant KRAS patients, other markers that can predict lack of response to this therapy. Small series have investigated the clinical effect of PIK3CA mutations on resistance to anti-EGFR mAbs and discrepant results have been observed. Furthermore, PTEN loss in metastases may be predictive of resistance to anti-EGFR mAbs, even if PTEN determination is far from an immediate clinical application. The introduction of modulators of the PI3K/AKT/mTOR …

PTENCancer ResearchClass I Phosphatidylinositol 3-KinasesPrognosiSettore MED/06 - Oncologia MedicaColorectal cancerCetuximabColorectal NeoplasmPhosphoinositide 3-kinasemedicine.disease_causePhosphatidylinositol 3-KinasesAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansPTENPanitumumabEpidermal growth factor receptorProtein kinase BPI3K/AKT/mTOR pathwayClass I Phosphatidylinositol 3-KinaseAntineoplastic Combined Chemotherapy ProtocolbiologyCetuximabAKTMTORPanitumumabPTEN PhosphohydrolaseAntibodies MonoclonalGeneral MedicinePrognosismedicine.diseaseErbB ReceptorsOncologyMutationbiology.proteinCancer researchReceptor Epidermal Growth FactorKRASPhosphatidylinositol 3-KinaseColorectal NeoplasmsProto-Oncogene Proteins c-aktHumanSignal Transductionmedicine.drug
researchProduct

Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy

2012

An area of therapeutic interest in cancer biology and treatment is targeting the cancer stem cell, more appropriately referred to as the cancer initiating cell (CIC). CICs comprise a subset of hierarchically organized, rare cancer cells with the ability to initiate cancer in xenografts in genetically modified murine models. CICs are thought to be responsible for tumor onset, self-renewal/maintenance, mutation accumulation and metastasis. CICs may lay dormant after various cancer therapies which eliminate the more rapidly proliferating bulk cancer (BC) mass. However, CICs may remerge after therapy is discontinued as they may represent cells which were either intrinsically resistant to the or…

PTENgerminal mutationchemotherapeuticmedicine.medical_treatmentAntineoplastic AgentsPI3KTargeted therapyMetastasisMice03 medical and health sciencesTARGETED THERAPY0302 clinical medicineCancer stem cellNeoplasmsradiologicalDrug DiscoverymedicineAnimalsHumansPTENAkt; mTOR; PI3K; PTEN; Targeted therapy; Therapeutic sensitivityPI3K/AKT/mTOR pathway030304 developmental biologyPharmacologyBiological Products0303 health sciencesbiologyAKTMTORAktCD44Wnt signaling pathwayCancertargeted therapymedicine.disease3. Good healththerapeutic sensitivityxenografts030220 oncology & carcinogenesisImmunologymTORNeoplastic Stem CellsCancer researchbiology.proteinCurrent Pharmaceutical Design
researchProduct

P(HPMA)-block-P(LA) copolymers in paclitaxel formulations: Polylactide stereochemistry controls micellization, cellular uptake kinetics, intracellula…

2012

In order to explore the influence of polymer microstructure and stereochemistry in biological settings, the synthesis, micellization, cellular fate and the use in paclitaxel formulations of poly(N-(2-hydroxypropyl)-methacrylamide)-block-poly(L-lactide) (P(HPMA)-block-P(LLA)) and poly(N-(2-hydroxypropyl)-methacrylamide)-block-poly(DL-lactide) block copolymers (P(HPMA)-block-P(DLLA)) were studied. To this end, P(HPMA)-block-P(lactide) block copolymers and their fluorescently labeled analogues were synthesized. The polymers exhibited molecular weights M-n around 20,000 g/mol with dispersities (D=M-w/M-n) below 1.3. In addition, the solution conformation of this new type of partially degradable…

PaclitaxelStereochemistryCell SurvivalPolyestersTacticityMolecular ConformationPharmaceutical ScienceMicellechemistry.chemical_compoundTacticityAmphiphilePolymer chemistryPolylactide block copolymersCopolymerHumansReversible addition−fragmentation chain-transfer polymerizationMicelleschemistry.chemical_classificationLactideRAFT polymerizationPoly(N-(2-hydroxypropyl)-methacrylamideBiological TransportPolymerStructure activity relationshipAntineoplastic Agents PhytogenicKineticschemistryDrug deliveryHPMA block copolymersMethacrylatesHeLa Cells
researchProduct